^
Association details:
| Biomarker: | FOLR1 expression |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | Rubraca (rucaparib) (PARP inhibitor) + Elahere (mirvetuximab soravtansine-gynx) (Microtubule inhibitor, Folate receptor 1-targeted antibody-drug conjugate) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
PHASE I STUDY OF MIRVETUXIMAB SORAVTANSINE (MIRV) AND RUCAPARIB FOR RECURRENT ENDOMETRIAL, OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER
Published date:
08/29/2021
Excerpt:
... >100 patients were screened for FRα expression; 21 have been enrolle, , 16 with ovarian and 5 with endometrial cancer. Sixteen patients are currently evaluable for response; 6 (37.5%) with PR, 8 (50%) SD, 2 (12.5%) PD; ORR 33% (4/12) in ovarian cancer and 50% (2/4) in endometrial cancer. Median PFS is 6.3 months with 95%CI (0.7, 13.8) months. Combination rucaparib and MIRV was tolerable with mostly manageable side effects and encouraging activity in this heavily pretreated population (including prior PARPi) of both endometrial and ovarian cancer.
